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ABSTRACT 
 
Background: Herpes Simplex Virus Type 2 (HSV 2) is one of the most common 
sexually transmitted infections (STIs) worldwide. HSV 2 infection is a risk factor for the 
acquisition and transmission of other STIs. 
 
Aim: The aim of this study is to determine prevalence and predictors of HSV 2 infection 
in Durban, South Africa by using available data that has not been previously analysed 
for the purpose of adding scientific evidence to the existing body of knowledge relating 
to HSV 2. 
 
Method: The study involves secondary analyses of data collected as a prospective 
study which enrolled women who participated in a clinical trial. A total of 3472 sexually 
active women were screened in the primary study from two clinics in Durban. All 
consenting participants were tested for HIV, HSV 2, Trichomonas vaginalis (TV), 
Neisseria gonorrhoea (NG) and Chlamydia trachomatis (CT) infection.  
 
Results: There were 2532 women who had HSV 2 giving a prevalence of 73%. Of 
these, 53% also tested positive for HIV infection.  In univariate analysis, co-infection 
with HIV was strongly associated with HSV2 (Odds Ratio (OR): 7.4, 95% Confidence 
Interval (CI): 6.0, 9.1, p<0.001). There was also an association between other STIs, 
such as CT, NG and syphilis and HSV 2, although only NG was significantly associated 
with prevalent of HSV 2 (OR: 2.3, 95% CI: 1.3, 4.1, p=0.005). Women older than 25 
years of age more likely to have HSV 2 (OR: 2.4, 95% CI: 2.0,2.8, p<0.001). A risk of 
being infected with HSV 2 increased with the number of  reported  lifetime sexual 
partners Those with two and three or more were 2,5 and 4.6 times more likely to have  
HSV2 respectively (OR: 2.5, 95% CI: 2.1,3.1, p<0.001 and OR: 4.6, 95% CI: 3.8, 5.6, 
p<0.001 respectively). Women who had less than high school education were also 
found to have higher risk for HSV 2.  
 
Conclusion: The secondary analysis showed a high prevalence of HSV 2 infection and 
a strong association of HSV 2 and HIV. A significant association of HSV 2 was noted in 
women having more than two sex partners and lower high school education. Therefore, 
it is recommended that screening for HSV 2 among high risk populations be 
incorporated into the STI screening and treatment packages. 
 
Key terms 
Sero-prevalence, Herpes Simplex Virus Type 2, HSV 2, sexually transmitted infection, 
HIV, genital ulcer disease, epidemiology, sexual behaviour. 
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CHAPTER 1 
 
STUDY BACKGROUND 
 
 
1.1 INTRODUCTION 
 
Herpes Simplex Virus Type 2 (HSV 2) infection has been found  to be more common in 
sub-Saharan Africa than in Europe or North America. Up to 82% of women and 53% of 
men in sub-Saharan Africa were seropositive for Herpes Simplex 2 (HSV 2),  the 
highest prevalence of HSV 2 infection in the world (Looker, Garnette & Schmid 
2008:805). HSV 2 is a sexually transmitted infection (STI) and the most common cause 
of genital herpes. In all populations studied HSV 2 infection is more common in women 
than in men as noted inastudy conducted at the University of Washington, International 
Clinical Research Centre in 2009, assessing suppression as a potential tool to prevent 
HIV transmission. This was a national study conducted in United States of America 
(USA) which also showed that one of five sexually active adults are infected with HSV 2. 
In Southern Africa about 50% to 70% of Human Immunodeficiency Virus (HIV) negative 
women have an HSV 2 infection (Karim, Karim, Frohlich & Grobler 2010:5996).  
 
The sub-Saharan region remains one of the areas hardest hit by Human 
Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS) 
epidemic. It is estimated that 22.5 million of people living with HIV globally and women 
in particular bear the greatest burden of the disease (UNAIDS 2008). South Africa has a 
much higher HIV prevalence than in the rest of the sub-Saharan region − 19% as 
compared to 6.1% in other regions. The HIV epidemic is fuelled partly by sexually 
transmitted infections as cited in the HIV/AIDS Policy fact Sheet (2011). Curable STIs 
play a greater role in HIV transmission and incurable STIs such as HSV 2 have a large 
impact on HIV acquisition. HSV 2 has emerged as the most prevalent STI pathogen and 
the most common cause of genital ulcer disease (GUD) worldwide  (Weiss 2004:24a-
35b).  The sub-Saharan region remains one of the areas hardest hit by HIV which is 
spread mainly by heterosexualtransmission (UNAIDS 2008). A study by Chen, Ballard 
and Beck (2000:21-29) showed 50% of men attending sexually transmitted disease 
clinics were infected with HSV 2. 
 
HSV 2 is transmitted sexually primarily from partners with asymptomatic or 
unrecognised infection. The presence of genital ulcers increases the risk both of 
acquisition and transmission of HIV.Randomised controlled clinical trials of herpes 
suppressive therapy on people living with HIV have shown that HIV alters the clinical 
presentation of HSV 2 infection in co-infected persons with low CD4 counts. This 
resulted in slow healing of the herpes ulcer leading to high levels of HIV and HSV 2 
genital shedding according to Delany, Clayton and Mlaba (2007). HSV 2 infection is an 
important public health concern because of the morbidity associated with symptomatic 
infections as well as the frequency of recurrence of this disease and its strong 
association with HIV acquisition. 
 
Primary prevention of the spread of HSV 2 infection is a vital strategy to reduce the 
increased risk of STI and HIV infection that is associated with HSV 2. Making aware of 
high HSV 2 prevalence in South Africa and the association with HIV infection and other 
STIs are important steps in addressing the increased risk for HIV infection. 
 
1.2 PROBLEM STATEMENT 
 
HSV 2 is the most common cause of genital ulcer disease and HSV 2 prevalence in 
sub-Saharan Africa ranges from 27% to 57% in men to 30 to 74% in women (Looker et 
al 2008:805). The HSV 2 prevalence  among commercial sex workers in Durban, South 
Africa in 2005 was 84%. Also in a study conducted by Ramjee, Willam, Van Dyk, De 
Deken and Karim (2005:333-339) in Durban, showed that 50% of the women recruited 
were living with HIV while 84 % were HSV 2 infected .  
 
Most persons who transmit genital herpes sexually have asymptomatic shedding and 
unrecognised lesions. Sexually transmitted infections especially HSV 2 is among the 
most well established risk factors for HIV infection. While it has been shown that HSV 2 
is a risk factor for HIV 1, few studies have been conducted to investigate the 
relationship between HIV1 other STIs and HSV 2 seroconversion. Therefore analysing 
this data will shed light on the risk factors posed in accquiring HSV 2. 
 
 
 
1.3 RATIONALE AND HYPOTHESIS FOR THE STUDY 
 Most persons who transmit genital herpes to a sex partner do not have a history of 
lesions at the time of transmission of the infection, suggesting that asymptomatic 
shedding and unrecognised lesions are responsible for most causes of transmission. 
While it has been shown that HSV 2 is a risk factor for HIV and other STIs few studies 
have been conducted in South Africa to determine prevalence of HSV 2, and its 
association with HIV1andother the associated risk factors. In research conducted on 
HSV 2. It is noted that an epidemiological synergy exists between sexually transmitted 
diseases including HSV 2 and HIV 1 and thus the control of one may have beneficial 
effects on the control of the other. Epidemiological studies on HSV 2 have consistently 
identified correlates of the disease. These risk factors can be categorised as socio-
demographic factors such as age, gender, education, socio-economic status and 
behavioural factors, such as number of sexual partners, type of relationship, sexual 
frequency and condom usage. However, there is limited data that is available about the 
South African population with regards to HSV 2 associated risk factors. Available data 
has mainly incident rates of HSV 2 and which are mostly older than 10 years.  
 
1.4 PURPOSE OF THE STUDY 
 
The purpose of this study is to analyse data to determine the prevalence and predictors 
of HSV 2 infection in Durban, South Africa, and to ascertain the risk caused by HSV 2. 
 
1.5 SIGNIFICANCE OF THE STUDY 
 
Firstly, the vast majorities of HSV 2 infections in adults are relatively asymptomatic in 
their clinical manifestations but yet increases the risk of acquiring other sexually 
transmitted infections. Therefore early identification is essential to manage this infection 
effectively. The high prevalence of HSV 2 globally indicates the need for adults and 
health care workers to be aware of the high prevalence of HSV 2 in order to better 
recognise symptoms, appropriately treat them to prevent transmission.  
 
Secondly, primary prevention of HSV 2 infection might be an important strategy to 
reduce the risk for HIV infection and other STIs associated with HSV 2. Showing the link 
between HSV 2 and associated risk factors are important first steps in addressing the 
epidemic.  
 Thirdly, the findings of this study should contribute significantly to the existing 
knowledge on the association of HSV 2 and HIV including the association with other 
STIs. Moreover the findings should assist and encourage a review of current health 
policies to adopt serological screening for HSV 2 among high risk populations when 
screening for other STIs. 
 
Fourthly, the findings of the study would have public health implications if a high 
prevalence of HSV 2 in the South African population is noted hence recommending 
research into development of an HSV 2 vaccine should continue. A HSV 2 vaccine is 
more likely to result in a more effective preventive measure in the future. 
 
Lastly, information from this study will add to the body of knowledge in the need to 
address high burden of co-occurring STI in people to prevent HIV transmission in a 
country which has one of the highest levels of HIV transmission. 
 
1.6 OBJECTIVES OF THE STUDY 
 
The objectives of this study are to determine: 
 
• the prevalence of HSV 2 in a cohort of women in the Durban area 
• association between HSV 2 in a cohort of woman in Durban area whose HSV 2 
status is unknown and who are at risk of acquiring HIV, Neisseria Gonorrhoea, 
Chlamydia Trachomatis and Trachomonis Vaginalis 
• HSV 2 acquisition with relationship to sexual behaviour patterns, demographic 
characteristics and socio-economic status 
 
NB: The primary study measured incident rate of HSV 2, HIV and other STIs 
through use of diaphgram as an investigational product. Therefore the above 
objectives are not replicated by the researcher in this study.  
  
1.7 DEFINITIONS OF KEY CONCEPTS 
 
Sero prevalence is the number of persons in a population who test positive for a 
specific disease based on serology (blood serum) specimens. 
 
Herpes Simplex Virus Type 2 (HSV 2) is a sexually transmitted disease (STD) caused 
by the herpes simplex viruses type 1 (HSV) or type 2 (HSV 2). Most genital herpes is 
caused by HSV 2. 
 
Sexually transmitted infection are illnesses that has a significant probability of 
transmission between humans by means of human sexual behaviour, including vaginal 
intercourse, oral sex, and anal sex. 
 
Human Immunodeficiency Virus is the virus that causes AIDS, a debilitating and 
deadly disease of the human immune system. 
 
Neisseria gonorrhoea are found within pus cells of the urethral and vaginal discharge. 
 
Chlamydia trachomatis. Gram negative bacteria that are parasites in humans which 
cause disease. 
 
Trachomonis vaginalis causes inflammation of the vagina associated with itching and 
increased vaginal discharge. 
 
Genital Ulcer disease. Ulcerativelesions on the genitals, usually caused by a sexually 
transmitted condition such as herpes, syphilis or chancroid. The presence of 
genital ulcers may increase the risk of transmitting HIV.  
 
Epidemiology: is the study of health-events, health-characteristics or health-
determinant patterns in a population. 
 
Socio-demographics refers to different groups of people within the society. In order to 
investigate socio-demographic variables focus is on age, gender, ethnicity, and socio-
economic status. 
Sexual behaviour. Human sexual behaviour refers to the manner in which humans 
experience and express their sexuality. 
 
Cohort of woman. A group of woman with a shared feature. 
 
For this study the cohort of woman will refer to woman who meet the eligibilty criteria set 
out in the primary study. 
 
(Concise Oxford Medical Dictionary 2007).  
 
1.8 RESEARCH DESIGN AND METHODOLOGY 
 
For this study an analytic, non-experimental design is appropriate to measure 
objectively the variables namely age, sex, educational level, marital status, condom use 
and coital frequency and statistically analyse and interpret the data. 
 
The study involved secondary analyses of data collected as a prospective study which 
enrolled women who participated in a clinical trial from November 2003 to November 
2006. The aim of this study is to determine prevalence and predictors of HSV 2 infection 
among women in Durban. 
 
A quantitative approach has been chosen for this study because quantitative research 
emphasises quantification and measurement of properties. The rationale is to measure 
the research variables associated with HSV 2. The study is non experimental as it will 
make use of existing data to quantify, describe and explore the existing phenomenon, 
that is, assessing prevalence of HSV 2 and noting the relationships between the 
disease and identified variables. 
 
1.9 SAMPLING 
 
This study will entail secondary data analysis whereby data has been collected but not 
yet analysed, thus sampling was determined by the primary study protocol and 
information provided on sampling here will be related to the primary study as only a 
subset of data will be extracted to meet the objectives of this study. 
The participants are women who have consented to participate in the ‘Methods for 
Improving Reproductive Health in Africa’ (MIRA) study. To be eligible for participation a 
woman had to fulfill a few criteria. The woman who had been HIV negative at the 
screening phase was one of the main eligibility criteria. Other eligibility criteria will be 
further noted in the methodology chapter. 
 
1.10 DATA COLLECTION  
 
Case report forms (CRF) was used to record all clinical and behavioural data and 
laboratory information obtained in the trial. Two types of laboratory testing was 
conducted i.e., on site testing was done for pregnancy and rapid HIV testing. Testing of 
samples was also done at local laboratories for Neisseria Gonorrhoea (NG), Chlamydia 
Trachomatis (CT) and Trachomonis Vaginalis (TV) and HSV 2. The total sample size 
was 3472 women who were recruited from November 2003 over two years and the 
study was completed in November 2006. 
 
NB: Due to this study being secondary analysis of data sampling, data collection will be 
further explained in the context of the primary study in chapter 3.  
 
1.11 DATA ANALYSIS 
 
Data will be analysed by a statistician using the Statistical Package for Social Science, 
(SPSS) IBM, Version 19.0. 
 
The statistical tests to be used for outcome measure will be: 
 
• Univariate and multivariate logistic regression methods to determine the 
predictors of HSV 2. This will be expressed by means of frequencies and 
percentages. 
• Cox Proportional Regression model will be used to determine the impact of HSV 
2 positivity. 
 
  
1.12 ETHICAL CONSIDERATIONS 
 
Ethics deal with matters of right and wrong. This implies that anyone involved in social 
scientific research should be aware of agreements shared by researchers and 
participants about what is proper and improper in the conduct of research (Babbie & 
Mouton 2002:470).  
 
In this study all rights of the participants, Medical Research Council of SA and funders 
were observed and respected. 
 
This study does not require participant consenting as written consent was obtained from 
all participants in the primary study. Howeve,r ethical consideration is discussed in the 
context of the primary study as the researcher identifies this as an important aspect in 
the research process.  
 
The ethical considerations included respect for the participants, privacy, autonomy, 
volunteerism, confidentiality and avoidance of harm. The ethical consideration will 
further be explained in chapter 3. 
 
1.13 LIMITATIONS OF THE STUDY  
 
The study is restricted to certain areas of South Africa and the data is based on women 
participating in clinical trials, thus limiting generalisability of HSV 2 infection rates to the 
general population and area of South Africa. This study deals with secondary analyses 
of data, hence a further limitation. Data maybe out of date since it was collected from 
2003 to 2006. However, this is valuable data for analysis as not many studies on HSV 2 
prevalence and associated risk factors are available regarding the South African 
population. 
 
1.14 CONCLUSION 
 
The control of HSV 2 is an important part of HIV and STI prevention strategy. The 
optimal strategy to achieve this is still being researched. Various studies conducted 
have concluded that HSV 2 is an important public health concern because of the 
morbidity associated with the infection, the strong association between HSV 2 and HIV 
infection and other STIs. The aim of this study is to determine the prevalence and 
predictors of HSV 2. The outcome from this study will add to the body of knowledge that 
addresses high levels of co-occurring STIs in people to prevent HIV transmission.  
  
CHAPTER 2 
 
LITERATURE REVIEW 
 
2.1 INTRODUCTION 
 
The literature review covers the key conceptswhich pertains to the topic. Key search 
words used to conduct a literature search on the electronic data base was HSV 2 and 
HIV prevalence, STIs, factors associated with HSV 2 and all other available information 
relating to the researchers understanding of the topic. The scope of the literature was 
broad enough to allow the researcher to become familiar with the research 
problem.(Burns & Grove 2007 b:136). In this chapter the researcher intends to show the 
phenomenon and relevancy of the topic through theoretical and empirical literature 
review. The topic under discussion will include HSV 2 sero prevalence, history of 
Genital Herpes Type 2, diagnosis of HSV infection, sexually transmitted co-infections, 
other risk factors associated with HSV 2 and intervention options. 
 
2.2 HSV SERO PREVALENCE 
 
HSV 2 is one of the most common sexually transmitted infections worldwide. The 
prevalence of HSV 2 is higher in developing countries than the developed countries 
(Weiss 2004:24a-35a). HSV 2 prevalence in sub Saharan Africa ranges from 27%−57 
% in men and 30%−74% in women (Looker et al 2008:805). 
 
According to Ramjee et al (2005:333-339), the HSV 2 prevalence rate among 
commercial sex workers in Durban, South Africa was 84%. This study further showed 
50% of the women were HIV 1 positive while 84% were HSV 2 positive indicating that 
the two infections were strongly associated. A population based study conducted 
among youth in Carletonville, South Africa, reported HSV 2 prevalence rate of 53.3% in 
females and 17 % among males and around 89% and 40% for females and males aged 
22−24 years (Auvert, Ballard, Campbell, Carael, Carton & Fehler (2001:885). In a meta-
analysis on the incidence and risk factors of HSV 2 infection, data showed that HSV 2 
incidence varied considerably across different countries, regions, and or populations. 
Africa and the United States were highly affected by HSV 2 and females were at higher 
risk of acquiring HSV 2 infection. 
 2.3 HISTORY OF GENITAL HERPES TYPE 2 
 
Herpes Simplex is divided into two types namely HSV type 1 and HSV type 2. HSV 1 
primarily causes infections in the mouth, throat, face, eyes and central nervous system. 
HSV 2 causes anal genital infections. The virus is a linear, double stranded DNA virus 
whose host are humans. Following a primary infection the virus enters the nerves at the 
site of primary infection, migrates to the cell body of the neuron and becomes latent in 
the ganglion. Herpes Simplex Virus is transmitted via close contact with infected bodily 
fluids such as salvia, genital fluids or fluids from active lesions as noted in Lafferty 
(2002:51-55). Herpes transmission occurs between discordant partners i.e. a person 
with a history of infection (HSV sero positive) can pass the virus to an HSV sero 
negative person. The only way to contact Herpes Simplex Type 2 is through direct skin 
to skin contact with an infected individual. HSV 2 asymptomatic shedding occurs at 
some time in most individuals infected with herpes. Asymptomatic shedding is more 
frequent within the first 12 months of acquiring HSV 2.The clinical manifestation of 
genital Herpes does not necessarily follow the described typical presentation of a 
prodromal illness that precedes the development of vesicles and ulcers. Laboratory 
testing is often used to confirm a diagnosis of genital Herpes.Not all cases of newly 
acquired HSV 2 infection presents with clinically apparent 
lesion http://en.wikipedia.org/wiki (accessed June 2011). 
 
2.4 DIAGNOSIS OF HSV INFECTION 
 
Clinical manifestation of patients with mucocutaneous disease is not always easily 
recognisable and in most cases may require laboratory testing. Viral culture is widely 
available and has been the gold standard for the diagnosis of HSV infection in patients 
with genital ulcers. Viral culture is highly sensitive for differentiating between HSV 1 and 
HSV 2. Isolation of the virus is easier in the vesicular or early ulcerative stages but 
sensitivity declines rapidly as the lesion begins to heal. Polymerase chain reaction 
testing for HSV DNA has greater sensitivity and relative affordability when compared to 
HSV culture. In Strick and Wald (2006:17) it is further noted that it has a sensitivity of 
greater than 95% compared with 75% for culture. However, the limitation for both tests 
is that they only focus on those with lesions. Type-specific serologic tests based 
glycoprotein G antibodies are the tests of choice to establish HSV infection when no 
lesions are present, but are still inaccessible in developing countries due to high costs. 
The challenges to serologic testing are that the test does not indicate when the infection 
was acquired, nor does it confirm the diagnosis of a lesion. The other limitation is 
performing both the HSV PCR and the serology test for routine management of patients 
with genital herpes infection in resource poor countries is costly and technical skill is 
required (Strick & Wald 2006:26-28). 
 
2.6 SEXUALLY TRANSMITTED CO-INFECTIONS  
 
Sexually transmitted infections (STIs) are among the most well established risk factors 
for HIV infection. STI facilitates HIV transmission by invasion of the protective mucosal 
barriers and allows susceptible immune cells, which are CD4 T-helper cells, 
microphages to the sites of infection as postulated in Ward,Ronn(2010:305).  Ulcerative 
and non-ulcerative STI creates portals of entry for HIV to access susceptible cells. 
People who are infected with HSV 2 are more likely to acquire and transmit HIV. This 
may be related to the inflammation of the genital mucus membranes and genital ulcers 
caused by HSV 2 which may provide a path for the entry and exit of HIV. The 
association between ulcerative STI and HIV transmission is well established, with as 
many as half of newly HIV infected people demonstrating HSV 2 infection as noted in 
Royce, Senq, Cates, (1997:190).  
 
Recent research by Seth, Pellowski and Turne (2011:183), examined STI in people 
already infected with HIV and concluded that the effects of HIV infection on immunity 
can increase susceptibility to other STIs as individuals who are immune compromised 
are less able to have a protective response against sexually transmitted pathogens. For 
example HIV and HSV 2 co-infections are prevalent and both infections can facilitate 
acquisition of the other. A study conducted by Tobian, Serwadda, Quinn, (2005:733), 
illustrate the reciprocal relationship between HIV and HSV 2; 6396 men in Uganda were 
followed for 2 years and found a 1.09% of HIV seroconversion rate in the cohort. 
However HIV seroconversion was closely associated with HSV 2 seroconversion, more 
than half (56%) of HIV and HSV 2 infection occurred in the same time frame. In 25% of 
cases, HIV infection preceded HSV 2 infection and in 19 % of cases HSV 2 infection 
preceded HIV transmission (Tobian et al 2005:735). Viral STI and genital ulcer 
diseases, particularly HSV 2 are also linked to increased concentrations of HIV in blood 
plasma and genital fluids. Various STIs differ in their impact on HIV shedding and 
acquisition. Overall, the greater the inflammatory response the greater the impact on 
HIV infectiousness is noted in Buchacz, Patel, Taylor (2004:275).Gonorrhoea and 
Chlamydia for example are associated with high concentrations of leucocytes in the 
genital tract and therefore greater HIV shedding. It is noted that STIs with greatest 
impact on HIV shedding are those that produce genital ulcers, urethral/vaginal 
discharge, specifically Chancroid, Gonorrhoea, Chlamydia, HSV 2, Trichomoniasis and 
Bacterial Vaginosis. HSV 2 is the leading cause of GUD in the developing countries and 
is especially prevalent among men who have sex with men (Seth, Pellowski & Turne 
2011:183). 
 
2.6 RISK FACTORS FOR HSV 2 INFECTION 
 
Epidemiologic studies in other countries have consistently identified correlates of HSV 2 
that can be mainly attributed to frequent sexual activity and cumulative exposure as 
noted in a study conducted by Weiss (2004).  These risk factors can be categorised as 
socio-demographic, that is, older age, female gender, low education status, socio-
economic status, behaviooral (number of sexual partners type of  relationship, sexual 
frequency and condom use). 
 
2.7 SOCIO-DEMOGRAPHIC FACTORS 
 
HSV 2 is more common in sub-Saharan Africa than in Europe or North America. Up to 
82% of women and 53% of men in sub-Saharan Africa are HSV 2 seropositive. These 
are the highest levels of HSV infection in the world, although exact levels vary from 
country to country. High HSV 2 sero prevalence has been observed for women in other 
African states such as Uganda and Zambia and in men mainly in Ethiopia (Weiss 
2004:24a-35a). 
 
Wiess (2004:24a-35a) further postulated that genital herpes appears less common in 
Northern Africa compared to sub-Saharan Africa. For example, only 26% of middle 
aged women have antibodies for HSV 2 in Morocco. Women are more likely to be 
infected with HSV 2 once they are over the age of 40 years. Children in Egypt are often 
infected with HSV 2 from a young age. HSV 2 or HIV 1 antibodies are present in an 
estimated 54% of children under the age of 5 years and 77% in children over 10 years 
of age. 
 
In general HSV 2 has been consistently found to be higher in women than in men. The 
possible reason for this difference can be explained by biological factors such as large 
surface area of the female genital mucosa which would increase the risk of acquisition 
and the general tendency for young women to choose sexual partners who are older 
than them. 
 
A number of population based prevalence studies of age related trends in HSV 2 have 
been conducted. In the US HSV 2 prevalence increased until approximately age 30 and 
then stabilised. In Australia, prevalence similarly peaked at midlife and then plateaued. 
In Ontario, Canada, HSV 2 prevalence did not stabilise but rather continued to increase 
through the oldest group studied, 40−44 years, a pattern suggesting additional men 
infection among middle aged adults. Countries such as Costa Rica and Switzerland 
have observed the highest prevalence among the most elderly men. In Switzerland 
elderly men believed to represent the war cohort. However, it is likely that an increase in 
prevalence with age also represents new infections occurring at older age, as 
postulated by Greta, Nooshin, Todd & Coleman (2010:10). 
 
Greta et al (2010:10) further noted in a survey conducted on the United States 
population from 1999–2008 by the United States National Health and Nutrition  
Examination Survey, results showed that those who were single or not married had a 
higher HSV 2 prevalence than those who were married or cohabitating. Among 
unmarried, 45–49 years old, seroprevalence was 55.3% in women and 25.7% in men.  
Relationship status remained an independent predictor of HSV 2 when controlling for 
age, race and sex among those age 30–49 years, married or cohabitating status was 
protective for HSV 2 in this groups(odd ratio=0.69 
 
2.8 BEHAVIOURAL FACTORS 
 
Studies have indicated an association between HSV 2 and a few numbers of sexual 
partners. This can likely be due to age of sexual debut, condom use and early detection 
and treatment of STIs. The early age of sexual debut is a marker of longer period of 
sexual engagement hence exposure to HSV 2.  In a socio-demographic study in Hall 
(SA Journal of Aids 2005) showed the correlates of Herpes Simplex Type 1 and 2, and 
concluded that age, sex, race and level of education independently predicted outcome 
of HSV subtypes. In a study conducted by Wald, Langenberg and Krantz (2005) 
showed that condoms if used correctly are the most effective method in preventing 
STIs. Consistent and correct condom use was found to be protective in susceptible 
women in HSV 2 sero incident studies. A sero incident study among monogamous 
heterosexual couples on suppressive antiviral therapy showed a beneficial effect of 
condom use (Corey, Wald, Patel, Saeka, Tyring, Warren.2004:350). In this study the 
couples who used condoms for  more than 90% of sex acts  showed lower HSV 2  
transmission rates. Condoms offer moderate protection against HSV 2 in both men and 
women, with consistent condom users having a 30 % lower risk of HSV 2 acquisition 
compared to those who never use condoms.  
 
2.9 INTERVENTION OPTIONS 
 
2.9.1 Primary prevention 
 
HSV 2 infection is an important public health concern because of the morbidity 
associated with the infection. Thus primary prevention of HSV 2 should be a key 
strategy of reducing the HSV 2 incidence since most asymptomatic individuals are 
unaware of their infection and they are considered at high risk for spreading infection. 
 
2.9.1.1 Behavioural counselling and barrier methods 
 
Behavioural counseling should be  aimed at identifying risky behaviour patterns, given 
that HSV 2 is a marker of sexual activity, educational interventions should target young 
persons especially women and promote behavioural changes. Risk reduction messages 
should include delaying sexual initiation, condom use, reducing concurrent partnerships, 
knowing one’s partner HSV 2 status and promotion of health seeking behaviour and 
identifying STI symptoms. Condoms offer moderate protection against HSV in both men 
and women. With consistent condom use, users have a 30% lower risk of HSV 2 
acquisition compared with those who never use condoms in Wald et al (2005). The virus 
cannot pass through a latex condom, however a condom’s effectiveness is limited 
because it does not prevent skin contact or bodily fluid contact with other unprotected 
areas. The use of condoms or dental dams also limits the transmission of Herpes from 
the genitals of one partner to the mouth of the other or vice versa (Gupta, Warren & 
Wald 2008:2127). 
 
2.9.1.2 Vaccine and microbicides 
 
A vaccine for HSV 2 prevention would be a primary method of choice to reduce the 
acquisition of genital Herpes. Currently there is no available vaccine in preventing HSV 
2. Vaccine for HSV 2 is currently undergoing clinical trials. Once developed they may be 
used to help with prevention or minimise initial infections as well as treatment for 
existing infections (Stanberry, Spruance, Cunningham, Bernstien, Minder, Sacks.  
2002:1652).  
Microbicide gels which prevent STIs in vitro are another option that would ideally offer 
women protection againsts STIs. The broader use of microbicide gel could reduce the 
incidence and prevalence of HSV 2, especially among the vulnerable populations.The 
gel would also be a unique tool for the prevention of HSV 2 by women who are not able 
to insist on a mutually faithful relationship or condom use with their male partners 
(Karim et al 2010:1168). These products are however still undergoing research on 
human participants currently. 
 
2.10 SECONDARY PREVENTION  
 
Currently there is no method to eradicate herpes virus from the body, but anti viral 
therapy is available for the treatment of genital herpes. Medication can reduce the 
frequency, duration and severity of outbreaks (Blower, Wald, Gershengorn, Wang & 
Corey 2004:1610). This study further notes thattherapy is effective when given at the 
onset of clinical symptom manifestation or prodromal phase. Long term suppressive 
therapy reduces clinical re occurrences by 70% to 80% in persons with frequent 
outbreaks, that is, 6 or more times per year, and by up to 90% in clinical and subclinical 
shedding of HSV 2. According to Blower et al (2004), suppressive therapy is likely to be 
more beneficial than episodic treatment because it reduces both the symptomatic and 
asymptomatic infection episodes of HSV infection. In this study it is suggested to 
identify and treat persons with increased frequency of HSV 2 reactivation and 
identification of high risk groups with newly acquired HSV infection such as sexually 
active young adults and individuals co-infected with HSV 2 and HIV infection.  
 
2.11 CONCLUSION 
 
HSV 2 is noted to be one of the most common sexually transmitted infections globally. 
Studies in sub-Saharan Africa showed that approximately 50% of people who are HIV 
uninfected have HSV 2 infection and between 60−90% of people who are HIV infected 
have HSV 2 infection. Further HSV 2 seems to be more common in women than in 
men. Data from multiple studies indicate that HSV 2 appears to be a major factor in 
fuelling the HIV epidemic.   
 
Data also show HSV 2 incidence varied among countries, regions and populations and 
is related to a number of sexual and demographic risk factors which calls for specific 
control strategies. However, the possible availability of an HSV 2 vaccine that is able to 
protect over 70% of women offers the best hope for control of genital herpes. 
Further,there is a need to enhance primary strategies which would be a key to reducing 
incident rate of HSV 2 infection. 
CHAPTER 3 
 
RESEARCH METHODS 
 
 
3.1 INTRODUCTION 
 
Research methodology entails a description of the study design, along with an 
explanation of how the population is selected and the criteria used for selection, a 
description of how data is collected as well as ethical issues are discussed. 
 
3.2 STUDY DESIGN 
 
This is secondary analysis .The primary study  included clear and organised activities 
with specific purpose to meet the specified objectives in the study. The process of 
research involves observation and analysis, planning is imperative in order to put in 
place what will be observed and analysed as dictated by the plan. 
 
For this study the researcher selected a quantitative design to measure objectively the 
variables involved and to statistically analyse and interpret the data. 
 
3.2.1 Quantitative research 
 
Literature describes quantitative research as descriptive and explorative with real life 
connotations that provide characteristics of the phenomenon to be studied. A 
quantitative approach has been chosen for this study because quantitative research 
emphasises quantification and measurement of properties. The rationale is to measure 
the research variables associated with HSV 2 to determine sero prevalence and 
incidence rates. 
 
The study is non-experimental, it makes use of existing quantitative data to describe 
and explore the existing phenomenon,which  is, assessing prevalence of HSV 2 and 
noting the relationship between the disease and identified variables. 
The data used in this study forms part of data collected in the primary study. This data 
meets the objectives of this study and is available for analyses as it was not used to 
evaluate the end points and objectives of the primary study. Therefore a subset of data 
will be abstracted to answer the research questions in this study. This data will be used 
to statistically analyse and interpret the outcomes in relation to the objectives set out. It 
is because variables are measured in this study quantitative research is the most 
suitable paradigm here.Non-experimental research design investigates situations and 
relationships in variables without manipulation of the independent variables (Polit & 
Beck 2008:763).   
 
3.4.2  Descriptive research 
 
Burns and Grove (2007:74) postulate that descriptive research aims at describing and 
exploring a phenomenon in real life situations, which include characteristics of a 
particular group of people or situations. The expectation is to give an overview of what 
exists and state the frequency of the occurrence of the events. 
 
3.4.3 Explorative research 
 
Babbie and Mouton (2002:80) describe explorative research as a quantitative study 
which enables researchers to discover new situations that can be described 
comprehensively to bring out clarity and meaning related to the phenomenon under 
study.The selection of the research design was based on the study objectives.In this 
study HSV 2, HIV and STIs are identified to be the dependentvariables.Demographic 
characteristics, risky sexual behaviour and age are independent variables. 
 
Data relating to the dependent and independent variable will be extracted from available 
data that was collected as part of a clinical trial,  which will be referred to as ‘primary 
study’, which was conducted in Durban, South Africa. This data has critical information 
that meets the objectives of this study and therefore will to be analysed and shared as 
scientific evidence. 
 
This data is available for analyses as it was not used to evaluate the end points and 
objectives of the primary study. A subset of data will be abstracted to answer the 
research questions in this study.This data will be used to statistically analyse and 
interpret the outcomes in relation to the objectives set out.The data that was used in the 
primary study was used to address a different research question and other objectives 
that have no relation to this study. 
 
Ethical approval in accordance with the guideline on human experimentation was 
obtained for the main study from the Biomedical Research Ethics Committee, University 
of KwaZulu-Natal, in Durban (see Annexure 1). The student sought permission from 
Medical Research Council/HIV Prevention Unit and the University of California, San 
Francisco, for use of data in this research project (see Annexure 2). Study no. 
NCT00121459 
 
3.5 RESEARCH METHODS 
 
3.3.1 Sampling 
 
This study utilises secondary data collected as part of a prospective randomised, 
controlled trial. Data will be analysed from two South African sites located in Durban. 
There are limited prevalence data available on HSV 2 prevalence and associated risk 
factors in South Africa and global studies have shown a strong association of HIV and 
STI acquisition and HSV 2 positivity, therefore it is appropriate to use available data to 
show prevalence. Therefore this secondary analyses of data is not only cost effective 
and time saving but will add value to studies conducted globally on HSV 2 indicating an 
urgent need to recognise and prevent HSV 2 infection among high risk populations.  
 
This study will entail secondary data analysis whereby data has been collected but not 
yet analysed, sampling was determined by the primary study protocol and information 
provided on sampling here will be related to the primary study.Although sampling was 
not done in the study,the researcher explains sampling to demonstrate understanding of 
the research process by the researcher. 
 
Study sites recruited woman from general health clinics, through community-based 
organisations, through word of mouth in the community, by using posters and leaflets in 
strategic areas. Educational materials were used to convey the key aspect of the study 
to potential participants, such as study objectives, inclusion and exclusion criteria and 
all study procedures were shared with potential participants. They were also informed of 
laboratory testing and study risk and benefits. 
 3.5.2 Study population 
 
Durban’s surrounding areas were the base for two groups of women who together 
comprise one cohort which made up the research population. One is peri-urban, and the 
other area is rural are whereby participants were drawn in Durban. It is important to 
include rural women in the study for generalisability and reasons related to public health 
policies. 
 
Durban is located along the Indian Ocean coast in the province of KwaZulu-Natal, the 
province in South Africa with the highest HIV incidence, 5.7 million in SA and 33% are in 
KZN (UNAIDS 2008). Between 1999 and 2000, HIV prevalence among women in their 
twenties in KwaZulu-Natal grew from 32.5% to 36.2% and incidence rates greater than 
10% have been reported in certain areas(UNAIDS 2008).  
 
3.5.3 Sample 
 
Woman who met the eligibility criteria was randomly selected from the Durban area. To 
be eligible for participation, a woman must satisfy the following criteria: 
 
• Age 18–49 years  
• Be sexually active (coital frequency of at least four times per month on average) 
• HIV negative 
• Willing and able to give informed consent. 
• Willing to provide blood sample for HIV, HSV 2 testing 
 
Total sample size for screening in both the Durban sites was 3472 women which started 
in November 2003 and ended in November 2006. For this  research project the sample 
of 3472 will be used to measure prevalence rate. 
 
 
 
 
3.6 ETHICAL CONSIDERATION 
 
Ethics basically refers to a system of moral principles suggested by a group or 
individuals. Ethics often go hand in hand with values, which deals with issues pertaining 
to what is right or wrong and good and desirable (Babbie & Mouton 2002:470). The 
following ethical aspect that was addressed in the primary study  included: 
 
3.4.1 Informed consent process 
 
The informed consent process was conducted in the language of participant’s choice 
which was either in English or Zulu. The consent form assured participants that their 
involvement in the interview was voluntary, that they had the right not to answer any 
questions that they wished not to answer or withdraw consent at any point of the 
research study and confidentiality was highlighted at all times. 
 
3.4.2 Maintaining confidentiality  
 
All study participants received a unique study identification number that was recorded 
on all paper forms. One electronic file linked participants name and study number was 
maintained by the study coordinator. This was done in order to maintain participant’s 
confidentiality. All records and specimens were identified by study number. Completed 
study forms were kept in lockable cabinets at the study sites. All records that contained 
names or other personal identifiers were kept locked separately from records identified 
by study staff.  
 
3.5 DATA COLLECTION 
 
Although data will not be collected in this study the researcher outlines the data 
collection instruments used in the primary study as this would ensure validity in the data 
proposed for use in this research study. 
 
Operational definitions with regards to data collection will be discussed with reference to 
the primary data collection whereby the researcher was directly involved in data 
collection. 
 
Standard Operating Procedures (SOP) and good clinical practice were tools used to 
ensure reliability, consistency and accuracy in data collection. Professional nurses and 
laboratory technicians were trained for data collection to ensure understanding and 
avoid errors and ambiguity and enhance standardisation. 
 
The researcher of this study was directly involved in development and review of (SOP) 
and data collection including blood sample collection in the capacity of a professional 
nurse. 
 
3.5.2 Methods and process:  Clinical and diagnostic procedures 
 
A written informed consent was obtained from all participants before commencement of 
study procedures. All procedures were performed by qualified, trained study staff. 
Diagnostic testing, answering an interviewer administered questionnaire known as case 
report form (CRF) demographics and sexual behaviour was performed. Participants 
received counseling before testing for HIV and other STIs. Urine specimens were 
collected for polymerase chain reaction (PCR) testing for Neisseria Gonorrhoea, 
Chlamydia Trachomatis and Trichomonas Vaginalis were done on site. HIV Rapid tests 
were performed on whole blood samples from finger pricks. Venous blood was collected 
by research nurse to be used to tests  for HSV 2.  
 
3.6 DATA ANALYSIS  
 
Data was analysed by a statistician using the SPSS IBM, Version 19.0. The statistical 
tests to be used for outcome measure will be: 
 
• Univariate and multivariate logistic regression methods to determine the 
predictors of HSV 2. This will be expressed by means of frequencies and 
percentages. 
• Cox Proportional Regression model will be used to determine the impact of HSV 
2 positivity. 
 
 
 
 
3.7 INTERNAL AND EXTERNAL VALIDITY OF THE STUDY 
 
Although the following relates to the primary study it is imperative to note that the 
integrity of the data proposed for use  has been collected through a rigourous scientific 
process ensuring reliability and validity therefore the researcher outlines the following 
that was undertaken in the primary study. 
 
3.7.1 Internal validity 
 
A pilot test was established to ensure that language and reading level of the 
questionnaires were appropriate. 
 
3.7.2 External validity 
 
This was enhanced by selection of population sample from two different communities 
mainly rural and peri urban this was to ensure generalisabiltiy of the population. 
 
3.8 LABORATORY PROCEDURES 
 
Many onsite tests were conducted at the study clinics and others were conducted in 
local outsourced laboratories, therefore special attention was paid to standardisation 
and quality control in both sites. All on site, local laboratory technicians were trained 
ensuring a consistent standard of quality. The local laboratory had to adhere to 
standards of good laboratory practice, had quality control procedures in place and 
ensured documentation of procedures that was performed. Internal controls provided by 
the manufacturers of automated tests and test kits were performed to ensure validity of 
test kits used. 
 
External monitors reviewed all laboratory source documents and laboratory result form, 
standard operating procedures for all tests performed as part of the study protocol, this 
included review of results to verify consistency. Special emphasis was placed on 
minimising transcription errors of test results by repeated quality checks performed by 
laboratory technicians. 
 
 
3.9 DATA PROCEDURES AND MANAGEMENT 
 
At each visit all CRFs are checked at site for accuracy and completeness. Information 
collected on study forms was checked by staff completing the forms, study coordinator 
and by monitors. This was done to detect errors, omissions and discrepant responses to 
questionnaires. In addition standard quality control procedures were established prior to 
data capturing to ensure the integrity of the data. CRF data was processed and 
reviewed using Datafax version 3.7 (clinical DataFax System Inc.). Original CRFs was 
compared against the database to verify the accuracy of the data. 
 
 
3.10 CONCLUSION 
 
Although this study entails secondary analysis of data this chapter describes the 
research design and methods used to collect data including the population sample, 
research instrument and ethical consideration specific to the primary study. By giving 
this information the researcher is able to demonstrate knowledge of the research 
process. In this study HSV 2, HIV and STIs are identified to be the dependent variables 
and demographic characteristics, risky sexual behaviour and age independent 
variables, which will be determinants of HSV 2.  
  
CHAPTER 4 
 
DATA ANALYSIS AND DISCUSSION 
 
 
4.1 INTRODUCTION 
 
According to McMillan and Schumacher (1993), the aim of analysing and interpreting 
research data is to test and achieve research objectives and provide answers to 
research objectives and to the research questions. In this study the researcher analysed 
and interpreted data from CRF and laboratory test results. For clarity and meaningful 
presentation of the study, bar graphs and pie charts were used. A discussion follows for 
comparison of the findings as guided by the relevant objectives. Therefore data analysis 
and research results will be discussed in this chapter. 
 
4.2 DATA ANALYSIS 
 
Statistical software ,IBM SPSS version 19.0 was used to generate  prevalence 
estimates and 95% confidence intervals. Prevalence was analysed by age group, 
education level, number of lifetime sex partners, marital status, condom use and other 
STIs. 
 
Demographic information including age, educational level, number of sexual partners 
and marital status and condom use was obtained through administration of case reports 
forms and all analysis was stratified as mentioned above with specific prevalence for 
HSV 2 positivity along with corresponding 95% confidence intervals. 
 
4.3 RESEARCH RESULTS 
 
4.3.1 HSV 2 prevalence and age 
 
In the population (N=3472) under study, 2532 women were HSV 2 sero positive a 
seroprevalence of 73% (95% CI). 
 
Older age was significantly associated with HSV 2 sero positivity.Whencompared to 
those younger than 25 years of age, older women were more likely to be diagnosed with 
HSV 2 (OR:2.37, 95% CI:2.00,2.81, p=,0001 and OR: 3.18, 95% CI: 2.55,3.95, 
p=<.0001 for 25−34 years and 35  years respectively). In those younger than 25 
years,34.7%(n=874) were sero positive between 25−34years 39.9%(n=1005) and less 
than 35 years 25.4% (n=639) were tested HSV 2 positive. This is in keeping with 
observations made in other studies conducted in African countries. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Prevalence of HSV 2 by age (N= 2532) 
 
4.3.2 Educational level 
 
For this analysis educational level was categorised as high school level or less than 
high school level. HSV 2 sero prevalence was higher among women obtaining lesser 
than high school education,76.9% (n=1949) when compared to those women who have 
obtained high school education 23.03% (n=583). Statistically significant correlation with 
p=<.0001 was noted between HSV 2 sero positivity and the level of education obtained. 
A low level of education may indicate lack of understanding in the cause of disease and 
illness and may further delay seeking treatment and intervention. 
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4.3.3 Relationship status  
 
Relationship status was assessed using the two categories, single or never married and 
married or cohabitating. For this analysis those who never married, divorced or widowed 
were grouped together as single, representing a population most likely to be available 
for or initiating new sexual relationships. Those who were cohabitating were classified 
as married to represent those unlikely to be initiating new sexual relationships. Among 
single women the overall prevalence of HSV 2 was low 13.6%(n=345) when compared 
to married/cohabitating women 86.4% (n=2187). 
 
4.3.4 Sexual partners and condom usage 
 
Measures of sexual activity included having any sex in the past month and having two 
or more sex partners in the past year. Sex was defined as vaginal, anal, oral sex with a 
male partner.Woman who reported to having two or more sex partners  28.4% (n=714) 
were likely to be diagnosed with HSV 2 compared to those who reported only one 
lifetime sexual partner 17.6% (n=443) (OR: 2.53, 95% CI: 2.08, 3.07, p=<.0001) 
respectively. A significant association was noted in never using condoms and HSV 2 
seroprevalence, 69.82% (n=1758) and women who reported always using condoms  
44.4% (n=1118). 
 
Table 4.1 Number of sex partners categorised by HSV 2 (N=3472) 
 
Number of sex partners HSV 2 screening 
Frequency 0 1 Total 
One partners 43.4% 
(n=414) 
17.6% 
(n=443) 
857 
Two partners 27.7% 
(n=264) 
28.4% 
(n=714) 
978 
Three partners 15.0% 
(n=143) 
23.4% 
(n=588) 
731 
Four partners 13.9% 
(n=133) 
30.7% 
(n=773) 
906 
Total 954 2518 3472 
 
  
Table 4.2 Baseline socio-demographic characteristic and sexual behaviour 
 
HSV 2 POSITIVE 
 Yes No P value 
Demographics 
Age (years) median (IQF) 
<25 34.7% (874) 58.3% (556) <.0001 
2–34 58.3% (1005) 28.3% (270) <.0001 
>35 25.4% (639) 13.4%  (128) <.0001 
Education    
High school 23.0% (583) 33.47% (321) <.0001 
Less than high school 77.0 (1949) 66.53 (638) <.0001 
Behavioural    
Regular sex partners 86.10% (2168) 80.40% (767) <.0001 
Casual sex partners 0.20% (5) 99.8% (2513) <.0001 
Number of sexual partners    
One sex partner 17.6% (443) 43.40% (414) <.0001 
Two or more partners 28.36% (714) 27.7% (264) <.0001 
Marital status    
Single (never married) 13.6% (345) 19.19% (184) <0.0001 
Married/cohabitating 86.4% (2187) 80.1% (775) <0.0001 
Condom use    
Never 69.8% (1758) 71.28% (680)  
Always 44.4% (1118) 47.48% (453)  
Positive laboratory results    
Chlamydia Trachomatis 8.9% (227) 8.9% (84) 0.9440 
Neisseria Gonorrhea 3.3% (83) 1.5% (14) 0.0042 
Trachomonis Vaginalis 6.3% (160) 5.9% (57) 0.68 
HIV 53% (1322)  <0.0001 
HSV 2 73% (2532)   
 
In the above table there were 2532 women who had HSV 2 giving a prevalence of  
73%. Of these, 53% also tested positive for HIV infection. Co-infection with HIV was 
strongly associated with HSV 2 with p<0.001). There was also an association between 
other STIs, such as CT, NG and syphilis and HSV 2, although only NG was significantly 
associated with prevalent of HSV 2 (p=0.005).Women older than 25 years of age more 
likely to have HSV 2 , p<0.001. A risk of being infected with HSV 2 increased with the 
number of  reported  lifetime sexual partners Those with two and three or more were 2,5 
and 4.6 times more likely to have HSV 2 respectively, p<0.001 and p<0.001 
respectively. Women who had less than high school education were also found  to have  
higher risk for HSV 2.  
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4.3.5 HSV 2 prevalence and co-occurring STIs and HIV  
 
The prevalence of HSV 2 was 73% (n=2532) of these 53 % were also tested positive for 
HIV infection. In univariate analysis co-infection with HIV was determined to be the most 
significant predictor for HSV 2 diagnosis, (OR: 7.38, 95 % CI, 6.01, 9.07 p=<0001). STIs 
such as CT, NG and TV was significantly associated with prevalence of HSV 2 (OR: 
2.28, 95% CI: 1.29, 4.05 p=0.005).The prevalence of HSV 2 co-infective with STIs are 
as follows. HIV=53%, CT=3.3%, TV=6.3%, NG=3.3%   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 Prevalence of HSV 2 co-infection with STI 
 
 
4.4 CONTRACEPTIVE USE  
 
Three methods of contraception used in this study were injectable, oral pill and 
vasectomy, 4.1% (n=142) of women were on oral contraception, while 1287(37%) were  
on an injectable method and a few 5 (0.14%) reported partners having a vasectomy 
done. About 22.5% (n=780) reported no contraception use from a sample population of 
3472. It is suggested that 36% (n=1258) of women used some other method of 
contraception other than those mentioned above. Of those women who reported no 
contraception use,17.4% (n=604) were HSV 2 positive. 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 Percentage of contraceptive method usage 
 
 
4.5 OVERVIEW OF RESEARCH FINDINGS 
 
The prevalence of HSV 2 was 73% (n=2532) of these, 53% also tested positive for HIV 
infection.  In univariate analysis, co-infection with HIV was determined to be the most 
significant predictor for HSV 2 diagnosis odds ratio (OR): 7.38 95%. Confidence Interval 
(CI): 6.01, 9.07, <0.001. STIs, such as CT, NG and syphilis, diagnosis with NG was 
significantly associated with prevalenceof HSV 2 (OR: 2.28, 95% CI: 1.29, 4.05, 
p=0.00). Compared to those <25 years of age, older women were more likely to be 
diagnosed with HSV 2 (OR: 2.37, 95% CI: 2.00,2.81, p<0.001 and OR: 3.18, 95% CI: 
2.55,3.95, p<0.001) for 25−34 years and 35 or older years respectively. Also compared 
to women who reported only one lifetime sexual partner, those who had two, three or 
more were likely to be diagnosed with HSV 2 (OR: 2.53, 95% CI: 2.08, 3.07, p<0.001 
and OR: 4.61, 95% CI: 3.83,5.55, p<0.001 respectively). Women who had less than 
high school education were determined to be in higher risk for HSV 2 seropositivity.  
 
  
4.6 CONCLUSION 
 
HSV 2 infection among women in particular is relatively high and confirms findings in 
other studies that sub-Saharan Africa has the highest HSV 2 sero prevalence in the 
world, at time reaching 80% in women by the age of 35 years.  
 
In this sero prevalent study detection of HSV 2 antibody is positively associated with 
increasing age, lower levels of education, increased number of sexual partners and 
decreased condom usage. Coinfection with HIV was determined to be the most 
significant prediction for HSV 2 diagnosis.  
  
CHAPTER 5 
 
CONCLUSION AND RECOMMENDATIONS 
 
 
5.1 INTRODUCTION 
 
The aim of this study was to determine prevalence and predictors of HSV 2 infection in 
Durban, South Africa by using available data that has not been analysed previously, in 
view of adding scientific evidence to the existing body of knowledge relating to 
HSV2.This chapter further discusses overall study findings, conclusion and 
recommendations. 
 
5.2 RESEARCH DESIGN AND METHOD 
 
A quantitative approach has been chosen for this study because quantitative research 
emphasises quantification and measurement of properties. The rationale wasto 
measure the research variables associated with HSV 2 to determine sero prevalence 
and risk factors. The study wasnon experimental as it made use of existing data to 
quantify and explore the existing phenomenon, which was, assessing prevalence of 
HSV 2 and noting the relationships between the disease and identified variables. 
 
This research study did not involve data collection as this study  entailed secondary 
data analysis, therefore data that was collected was determined by the primary study 
protocol. 
 
5.3 SUMMARY AND INTERPRETATION OF THE RESEARCH FINDINGS  
 
5.3.1 HSV 2 positive 
 
This study demonstrates high HSV 2 infections at 73% (n=2532) prevalence among 
women aged 18 to 49 years old. A study conducted by Ramjee et al (2005:333-339) in 
South Africa have also shown a significantly high HSV 2 prevalence in females. 
Infection with HSV 2 produces a diverse spectrum of diseases and more often than not 
this infection in adults is clinically asymptomatic but causes significant discomfort and 
anxiety among millions of people. Genital HSV puts individuals at increased risk of 
acquiring other sexually transmitted infections including HIV. 
 
5.3.2 HSV 2 and HIV co-occurring infection 
 
The high prevalence of HSV 2 and HIV  infection among the cohort of women in this 
study is in keeping with those reported from Africa and other regions, in high risk 
groups. The odds ratio for HIV and HSV 2 found here confirms (OR=7.38, p=0.001) 
results of other studies which have shown a strong association between HIV 1 and HSV 
2. The strength of associations between HIV and HSV 2 and the high prevalence of 
HSV 2 in many developing countries may be important in explaining the very high rates 
of HIV in those settings. Epidemiological studies in Ward et al. (2010:305)  and Buchacz 
et al (2004:275) support the hypothesis that HSV 2 increases the efficiency of HIV and 
STI acquisition and transmission. Similarly HIV may increase susceptibility to HSV 2, 
viral shedding and a low CD 4 count. It is further noted that HIV acquisition risk is 
highest among those with recent HSV 2 infection which may reflect the higher frequency 
and severity of herpetic ulcers in the early stages of HSV 2. It is not clear which 
infection comes first but HIV and HSV 2 persons experience severe frequent genital 
herpes syndromes and also have higher HSV 2 and HIV shedding from the genital tract. 
If anti-herpes treatment is not included in management of genital ulcer diseases, 
delayed ulcer healings result in prolonged HIV shedding and increase risk of HIV 
transmission. However, the decision about who would benefit from anti-herpes 
treatment and what screening tools used still pose a dilemma for policy makers. The 
high level of HIV and HSV 2 co-infection suggest that episodic and possibly long term 
suppressive therapy would be of benefit in the reduction time to healing of ulcers and 
HSV 2 and HIV shedding for those participants who have clinically HSV 2 symptoms if 
started early.   
 
5.3.3 HSV 2 and STIs 
 
Asymptomatic STIs are especially concerning as these infections worsen and if 
untreated does not alert the person to reduce risky sexual practices. If an individual 
presents with an STI, chances of having more than one STI are high due to risky sexual 
behaviour. In this study the prevalence of NG, CT, TV was significantly associated with 
HSV 2 infection. 
The correlation between HSV 2 antibody and TV was more marked than that between 
HSV 2 and other laboratory confirmed STIs. In Machekano, Bassett, Zhou, (2000)  
postulated that the greatest prevalence of STI co-infections occur among individuals 
newly diagnosed with HIV. In this study people who tested HIV positive at the time of 
STI testing found an average STI prevalence of 19.6 %.  In this study the prevalence of 
HSV 2 co-infective with STIs are as follows, HIV (53%), CT (3.3%), TV (6.3%), NG 
(3.3%). High rates of co-occurring STI will continue to impede efforts to prevent HIV 
transmission if efforts to prevent HIV transmission if primary prevention and treatment is 
not sort early. HSV 2 confers genital tract immunological changes which increase the 
risk of acquiring other STIs. Immnunological changes in the genital tract have 
demonstrated to enhance STIs. It is possible that control of HSV 2, would not only 
control the HIV infection but other STIs as well. 
 
5.3.4 HSV 2 and socio demographic risk factors 
 
The prevalence of HSV 2 infection occurs with some population bearing a greater 
burden of disease than others. Many observational prospective and retrospective 
studies have identified potential risk factors that influence HSV 2 transmission. Major 
factors associated with HSV 2 sero positivity includes female gender ,history of sexually 
transmitted infections, increasing numbers of sexual partners, low socio-economic 
status, level of education and age related risk factors.  
 
In this study older age was significantly associated with HSV 2 sero positivity. This 
result is in keeping with other studies. HSV 2 prevalence increased with age peaking at 
the 25−35 age groups and leveling off after age greater than 35 years. For age lesser 
than 25 years old, 34% of women had HSV 2 antibodies suggesting that HSV 2 
infection occurs during the first few years following sexual debut. It is likely that an 
increase in prevalence with age also represents new infections occurring at older age. 
Information on age and prevalence of HSV 2 is essential to optimise control strategies. 
 
Participants who reported having two or more lifetime sexual partners were more likely 
to be diagnosed with HSV 2 than those who reported only one lifetime sexual partner. 
The association between lifetime number of sexual partners and HSV 2 is consistent 
with other studies and this indicates a measure of increased sexual activity. 
In other sero prevalent studies socio-demographic markers such as married or 
cohabitating was associated with an increase risk of HSV 2 infection. This study affirms 
these findings, being married or cohabitating was statistically significant with HSV 2 
sero prevalent of 86.37% women that were married or cohabitating were HSV 2 positive 
as compared to 13.63% of women who were single or never married. This finding is 
more likely to be due to changes in relationship and family structure with an increasing 
proportion of adults outside of long term monogamous relationships. Over the life 
course relationship changes due to divorce, separation or death which leads to new 
patterns of casual dating, short term monogamous relationships or remarriage. 
 
A high percentage of not using condoms with HSV 2 prevalence (69.8%) was noted 
when compared to always using condoms (44.4%). This explains that women are not 
always able to negotiate condom use, although consistent and correct use of condoms 
by men remains the most effective form of protection from acquiring STIs. Possible 
reasons for women not being able to negotiate condom use maybe because of socio-
cultural constraints and power differentiates in gender roles. A study by Wald et al 
(2005), showed that participants reporting more condom use (condom use for >75% of 
sexual acts) were at a lower risk of acquiring HSV 2 (95%, CI:0.6 to 0.9). 
 
5.4 CONCLUSION 
 
In summary the prevalence of HSV 2 2 infection was high in the studied population. 
Potential risk factors that influenced HSV 2 transmission rates have been identified and 
this were categorised as biological behavioural and socio-demographical aspects. 
These risk factors could be an indication of population subgroups that are likely to have 
acquired or are at high risk of acquiring HSV 2. Important associated co-factors of HSV 
2 infection include females, history of STIs and having more than one sexual partner 
and added to this is low level of education and age related factors. In addition this data 
supports an important role of HSV 2 in facilitating HIV 1 transmission and acquisition. 
Understanding and identifying these risk factors may assist in interventions and 
programmes to reduce HSV 2 transmission and acquisition. 
 
The findings in this study have important public health implications in South Africa, 
being a country that’s greatly hit by the HIV epidemic. Therefore multifaceted 
interventions are needed to improve recognition of genital herpes and also to prevent 
it’s potential to promote HIV transmission.The high prevalence of HSV 2, almost 82% of 
woman in sub-Saharan Africa, and a strong association between HSV 2 and HIV is an 
important public health implication even more so in in this country whereby 
approximately 5,24 million are infected by HIV and  more importantly  testing for HSV 2 
is not a routine requirement in the management of sexually transmitted diseases. 
 
5.5 RECOMMENDATIONS 
 
It is recommended that primaryprevalence studies be conducted on HSV2 in different 
provinces as data analysed in this study was restricted to one province only therefore 
for generalisability to the entire country.The most cost effective intervention of curbing 
the transmission and acquisition of all STIs is primary prevention. Given the epidemic of 
HSV 2 acquisition as primarily an incident infection among young adults, this group 
should be prioritised especially in resource poor settings where incidence and 
prevalence remains highest. 
 
Primary prevention should include the following: 
 
• A need to recognise HSV2 infection among populations at risk and to provide 
treatment and counseling on condom use. 
• Priority to be given to integrate HSV2 and HIV1 prevention efforts in high risk 
populations given the strong association of HSV2 and HIV infections.  
 
5.6 CONTRIBUTION OF THE STUDY 
 
This study showed high prevalence rate of HSV 2 and associated risk factors, which is 
in keeping with high prevalence of HSV 2 globally. Primary prevention of HSV 2 
infection might be the only available strategy to reduce the risk for HIV and STI infection 
associated with HSV 2. Therefore increasing the awareness of the high HSV 2 
prevalence in South Africa and the link between HSV 2 and HIV infections are important 
first steps in addressing the epidemic. The findings of this study should contribute 
significantly to the existing knowledge on the association of HIV and HSV 2 including 
the association with other STIs. Moreover the findings should assist and encourage for 
a review of current health policies to adopt serologic  screening for HSV 2 among high 
risk populations when screening for other STIs .Lastly findings of the study have public 
health implications  if a high prevalence of HSV 2 in the South African population is 
noted hence recommending  research into development of an HSV 2 vaccine should 
continue  which is more likely to result in a more effective preventive measure in the 
future.  
 
5.7 LIMITATIONS  
 
The following limitations relates to the primary study which contributed to the subset of 
data used for this analysis.  
 
The study was restricted to certain areas of South Africa only and the data is based on 
women participating in clinical trials, this limiting generalisability of HSV 2 infection rates 
to the general population. This is selection bias because the women who opted to join a 
clinical trial maybe different from women in the general communities in possibly 
significant ways. The selection of women participating only may result in 
misclassification bias whereby this creates a construct to categorise women as having 
positive/negative and high /low outcomes than compared to males thus a possibility of 
misclassifying women. 
 
A further limitation of this study was the inability to determine temporal relationships of 
HIV, STIs and HSV 2 infection. The study also relied on self reported sexual behaviour, 
which is subject or recall bias and social desirability bias in the case of sexual 
behaviour.   
 
This study deals with secondary analyses of data, however, this is valuable data for 
analysis as not many recent studies on HSV 2 prevalence and associated risk factors 
are available regarding the South African population. 
 
  
5.8 CONCLUDING REMARKS 
 
The aim of this study was to determine HSV 2 prevalence and co-occurring infection 
and its correlates with socio-demographic and behaviour variables which the researcher 
was able to identify and analyse. 
 
This study showed a high prevalence of HSV 2 infection and a strong association of 
HSV 2 and HIV. A significant association of HSV 2 was noted in women having more 
than 2 sex partners and lower high school education. Therefore, it is recommended that 
screening for HSV 2 among high risk populations be incorporated into the STI screening 
and treatment packages.  
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